The metabolite alpha-ketoglutarate inhibits vascular calcification partially through modulation of the TET2/NLRP3 inflammasome signaling pathway.

Mingwei Fu, Zirong Lan, Yuanzhi Ye, Yuan Gong, Qingchun Liang, Mingxi Li, Liyun Feng, An Chen, Qianqian Dong, Yining Li, Siyi Wang, Xiaoyu Liu, Xiuli Zhang, Jing-Song Ou, Lihe Lu, Jianyun Yan

Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation; Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease; Sino-Japanese Cooperation Platform for Translational Research in Heart Failure, Guangzhou, China. · pubmed

Paper

Abstract

Vascular calcification is prevalent in chronic kidney disease (CKD), but existing medical treatments fail to achieve satisfactory therapeutic effects. Vascular calcification is now recognized as an active multifactorial process involving diverse mechanisms. Alpha-ketoglutarate (AKG), an intermediate in tricarboxylic acid cycle, has been demonstrated to extend lifespan and ameliorate age-related osteoporosis. However, whether AKG inhibits vascular calcification remains unknown.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that alpha-ketoglutarate inhibits vascular calcification through modulation of the TET2/NLRP3 inflammasome signaling pathway. The research addresses a mechanism related to aging and chronic kidney disease, which are pertinent to longevity and age-related diseases.

Author of this paper? Send a correction.